24/06/2019: Over the last years, Ergobyte has been investing in the development of RxReasoner, a novel clinical decision support tool able to provide real-time medication recommendations and run drug-to-drug and drug-to-disease interaction checks. RxReasoner has been selected among hundrends of applications to get support by EIT Health Headstart Programme.
The overall project goal is to prepare RxReasoner's launch into European markets. The activities supported by EIT Health Headstart are the following:
- English version development
- Validation and fine-tuning
- Expansion and marketing plan elaboration
- IPR management
Currently, RxReasoner receives acclaim from thousands of health professionals in Greece. Together with another 15 european start-ups and SMEs, Ergobyte's team will go through an intensive accelaration period that will lead to its first steps into European markets.
About EIT Health
EIT Health accelerator is a business creation programme aiming at supporting the best and brightest health industry entrepreneurs. It creates a favourable environment for innovation, providing skills and services to get promising business ideas into the market. In particular, the Headstart Programme provides funding to support early stage companies and SMEs in developing new products and services that address EIT Health challenges: healthy living, active ageing and improved healthcare.
